Drreddys Laboratories reported INR13.29B in Cash and Equivalent for its fiscal quarter ending in September of 2026.





Cash And Equivalent Change Date
ANI Pharmaceuticals USD 420.76M 60.55M Sep/2026
Aurora Cannabis CAD 69.31M 4.62M Jun/2026
Bayer EUR 4.29B 1.44B Jun/2026
Canopy Growth CAD 336.62M 28.06M Jun/2026
Cipla INR 16.59B 6.41B Sep/2026
Corcept Therapeutics USD 98.72M 12.32M Sep/2026
Drreddys Laboratories INR 13.29B 2.07B Sep/2026
GlaxoSmithKline GBP 3.1B 337M Jun/2026
Hikma Pharmaceutical USD 217M 19M Dec/2025
Lonza CHF 719M 188M Dec/2025
Novartis USD 8.87B 1.25B Sep/2026
Phibro Animal Health USD 75.55M 14.13M Sep/2026
Prestige Brands USD 46.52M 42.61M Sep/2026
Richter Gedeon HUF 135.63B 61.59B Dec/2024
Sun Pharmaceuticals INR 97.71B 15.61B Mar/2026
Supernus Pharmaceuticals USD 175.88M 4.07M Sep/2026
Teva Pharmaceutical Industries USD 4.08B 430M Sep/2026